

K062395

MAY - 9 2007

## 510(k) Summary: ACCU-CHEK® Smart Pix Device

---

**Introduction** According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

---

**Submitter  
name, address,  
contact** Roche Diagnostics  
9115 Hague Rd.  
Indianapolis, IN 46250  
Contact Person: Scott Thiel  
Data Prepared: March 27, 2007

---

**Device Name** We claim substantial equivalence to the current legally marketed ACCU-CHEK® Acculink Modem.

---

**Device  
Description** Accessory to ACCU-CHEK® brand meters and/or Disetronic/ACCU-CHEK insulin infusion pump that enables the persons with diabetes or healthcare professionals to send stored data to a compatible computer.

---

**Indications for  
Use Statement** The ACCU-CHEK® Smart Pix enables persons with diabetes or healthcare professionals to send stored data from their compatible ACCU-CHEK blood glucose monitor and/or Disetronic/ACCU-CHEK Insulin infusion pump to a compatible computer as a set of reports or data stream.

The ACCU-CHEK Smart Pix is intended to help monitor and clinically manage individuals with diabetes.

---

*Continued on next page*

## 510(k) Summary: ACCU-CHEK® Smart Pix Device, Continued

### Similarities

The proposed modification is relatively modest in scope. The following is a list of some of the claims and features unaffected by the proposed modifications.

Feature / Claim	Detail
Connect to blood glucose monitors	Both devices connect to and download information stored on ACCU-CHEK brand blood glucose monitors.
Warnings and precautions	For in vitro diagnostic use only.
State Messaging	Both devices provide feedback to the consumer through a combination of LED flashes.
Reports	Both devices create reports and graphs using basic statistical calculations of the historic data stored in the devices they can connect to.

*Continued on next page*

## 510(k) Summary: ACCU-CHEK® Smart Pix Device, Continued

### Differences

The following is a listing of the key differences between the ACCU-CHEK Smart Pix and the predicate device.

Feature / Claim	ACCU-CHEK Smart Pix	Predicate
Power supply	USB port	AC adapter
Weight	90 g	205 g
Size	104 x 74 x 38 mm	137 x 113 x 41 mm
Intended use	<p>The ACCU-CHEK® Smart Pix enables persons with diabetes or healthcare professionals to send stored data from their compatible ACCU-CHEK blood glucose monitor and/or Disetronic/ACCU-CHEK Insulin infusion pump to a compatible computer as a set of reports or data stream.</p> <p>The ACCU-CHEK Smart Pix is intended to help monitor and clinically manage individuals with diabetes.</p>	<p>The ACCU-CHEK® Acculink modem is designed to enable the self-tester to send data from a supported Accu-Chek brand meter to either a facsimile (fax) machine or Roche supported software utilized by a physician, pharmacist, or other member of the self-tester's health care team. The data transmission takes place over standard telephone service (POTS) lines or telephone line emulator.</p>
Ambient conditions	<p>Service temperature: 5 – 40 C</p> <p>Storage temperature: -25 – 70 C</p> <p>Humidity: 9.6 – 98% Rh</p>	<p>Operating temperature: 0 – 50 C</p> <p>Storage temperature: -25 – 65 C</p> <p>Humidity: 0 – 95% Rh</p>



Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

MAY - 9 2007

Roche Diagnostics Corp.  
c/o Mr. Scott Thiel  
Global Regulatory Affairs  
Diabetes Care  
9115 Hague Road  
Indianapolis, IN 46256

Re: k062395  
Trade/Device Name: ACCU-CHEK® Smart Pix  
Regulation Number: 21 CFR §862.1345  
Regulation Name: Glucose test system  
Regulatory Class: Class II  
Product Code: NBW, LZG, JQP  
Dated: March 28, 2007  
Received: March 29, 2007

Dear Mr. Thiel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in cursive script that reads "Jean M. Cooper, M.S., D.V.M.".

Jean M. Cooper, M.S., D.V.M.

Director

Division of Chemistry and Toxicology

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K062395

Device Name: ACCU-CHEK® Smart Pix

Indications For Use:

The ACCU-CHEK® Smart Pix enables persons with diabetes or healthcare professionals to send stored data from their compatible ACCU-CHEK blood glucose monitor and/or Disetronic/ACCU-CHEK Insulin infusion pump to a compatible computer as a set of reports or data stream.

The ACCU-CHEK Smart Pix is intended to help monitor and clinically manage individuals with diabetes.

Prescription Use XX  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use XX  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Jean M. Cooper, M.S., D.V.M.  
Division Sign-Off

Office of In Vitro Diagnostic  
Device Evaluation and Safety

Page 1 of 1

510(k) K062395